SG Americas Securities LLC Sells 10,113 Shares of LivaNova PLC (NASDAQ:LIVN)

SG Americas Securities LLC lessened its holdings in LivaNova PLC (NASDAQ:LIVN) by 78.1% during the third quarter, HoldingsChannel.com reports. The firm owned 2,844 shares of the company’s stock after selling 10,113 shares during the period. SG Americas Securities LLC’s holdings in LivaNova were worth $149,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Hexagon Capital Partners LLC increased its stake in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares during the last quarter. Fifth Third Bancorp raised its holdings in LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after acquiring an additional 332 shares in the last quarter. Lazard Asset Management LLC acquired a new position in LivaNova during the first quarter valued at approximately $84,000. Canada Pension Plan Investment Board bought a new position in LivaNova in the second quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC acquired a new position in shares of LivaNova during the 1st quarter worth approximately $94,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN stock opened at $53.00 on Friday. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -88.33 and a beta of 1.00. The company has a 50-day simple moving average of $50.40 and a 200 day simple moving average of $53.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. The company had revenue of $318.60 million during the quarter, compared to analysts’ expectations of $305.05 million. On average, sell-side analysts predict that LivaNova PLC will post 2.58 earnings per share for the current year.

Analysts Set New Price Targets

LIVN has been the subject of several recent analyst reports. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $55.00 to $66.00 in a report on Tuesday, September 17th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Needham & Company LLC boosted their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Stifel Nicolaus upped their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $69.83.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.